GlassScriptPhysician profile
Adrienne Potts
NPI 1750408670
$4,110.86
in general payments reported to CMS, 2019-2025
36 companies · $697 in 2025
The $697 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $454 · 2021: $1,096 · 2022: $682 · 2023: $332 · 2024: $371 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.84 | 2019-2025 | |
| Astellas Pharma US INC | $455.39 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $276.92 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $276.50 | 2021-2025 | |
| Pfizer INC. | $223.59 | 2020-2023 | |
| Mylan Pharmaceuticals INC. | $221.57 | 2019-2022 | |
| Therapeuticsmd, INC. | $194.66 | 2019-2022 | |
| Organon LLC | $178.24 | 2021-2025 | Nexplanon |
| Cumberland Pharmaceuticals, INC. | $166.50 | 2019-2024 | Kristalose |
| Renovia INC | $152.10 | 2021 | |
| Evofem Biosciences, INC. | $114.87 | 2021-2023 | Phexxi |
| Merck Sharp & Dohme LLC | $112.92 | 2019-2022 | |
| Millicent US INC | $109.44 | 2019-2025 | Intrarosa, Femring |
| Coopersurgical, INC. | $104.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.91 | 2020-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $97.33 | 2020-2022 | |
| Amgen INC. | $79.69 | 2021-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $63.24 | 2024-2025 | Myfembree |
| Myovant Sciences INC. | $57.48 | 2021 | |
| Avion Pharmaceuticals | $46.79 | 2021-2022 | |
| Hologic Sales and Service, LLC | $42.13 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Sage Therapeutics, LLC | $42.05 | 2019-2024 | |
| Gilead Sciences, INC. | $33.95 | 2025 | |
| Agile Therapeutics, INC. | $30.95 | 2021 | |
| Allergan, INC. | $30.63 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $29.46 | 2019-2020 | |
| Mission Pharmacal Company | $28.49 | 2019 | |
| Aspira Women'S Health INC | $25.19 | 2021 | |
| Corcept Therapeutics | $24.97 | 2021 | |
| Vertical Pharmaceuticals, LLC | $24.91 | 2019-2020 | |
| Meditrina | $23.19 | 2024-2025 | |
| Scynexis, INC. | $19.23 | 2022 | |
| Channel Medsystems, INC. | $18.71 | 2023 | |
| Medicem INC. | $17.91 | 2021 | |
| Lupin INC. | $13.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.